bioRxiv · 10.1101/2020.12.14.422718
Remdesivir is a delayed translocation inhibitor of SARS CoV-2 replication in vitro
Abstract
Remdesivir is a nucleoside analog approved by the FDA for treatment of COVID-19. Here, we present a 3.9-[A]-resolution cryoEM reconstruction of a remdesivir-stalled RNA-dependent RNA polymerase complex, revealing full incorporation of three copies of remdesivir monophosphate (RMP) and a partially incorporated fourth RMP in the active site. The structure reveals that RMP blocks RNA translocation after incorporation of three bases following RMP, resulting in delayed chain termination, which can guide the rational design of improved antiviral drugs.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Bravo, J. P., Dangerfield, T. L., Taylor, D. W., Johnson, K. A.. 2020-12-16. Remdesivir is a delayed translocation inhibitor of SARS CoV-2 replication in vitro. https://doi.org/10.1101/2020.12.14.422718
Cite the original work for its findings. Save a collection to share your selection of sources.